Skip to main content

Page last checked

Symptom question · incretin class

Does a GLP-1 cause burping?

None of the 36 compound guides checked lists burping as a reported side effect. 25 have published safety information that does not mention it. BPC-157, TB-500, GHK-Cu, MOTS-c, Epitalon, Kisspeptin-10, IGF-1 LR3, PEG-MGF, KPV, Selank and AHK-Cu have no published human safety data.

Source: checked against 36 compound guides; rates are shown exactly as reportedFDA label

FDA data lists belching among the twenty-five most-reported terms for two of eight brands, and both contain tirzepatide. For the other six, the term falls below each product’s cut-off; that does not mean zero reports.

The two sources disagree because they measure different things. A side effect may be absent from a label summary yet common in reports filed after a product reaches the market.

People most often search this with Zepbound or Mounjaro, sometimes adding the word sulfur. Both brands contain tirzepatide, and FDA reports show the general belching term for both.

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer

Information checked 2026-08-20

At a glance

Compounds that list it

0 of 36

Only in a combined category

0

No published human safety data

11

Best available source

FDA label

Which compounds list burping

None of the labels or trials checked lists burping as a reported side effect. FDA reports filed after the medicines went on sale tell a different story, so those results appear in a separate table below.

◆ Burping across 36 compoundssource shown for every row
Every compound covered on this site, showing whether it lists burping and at what frequency its own cited source states.
CompoundHow it appearsFrequency reportedSource type
TirzepatideZepbound, MounjaroNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
SemaglutideWegovy, Ozempic, RybelsusNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
LiraglutideVictoza, SaxendaNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
RetatrutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
CagrilintideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
SurvodutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
BPC-157No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
TesamorelinEgrifta SV, Egrifta WRNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
PT-141VyleesiNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
CJC-1295Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
IpamorelinNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
TB-500No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
GHK-CuNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
SermorelinNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
MOTS-cNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
AOD-9604Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
NAD+Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
EpitalonNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
Kisspeptin-10No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
DSIPNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
HexarelinNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
IGF-1 LR3No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
PEG-MGFNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
LL-37Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
KPVNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
Thymosin alpha-1Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
SS-31ForzinityNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
SemaxNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
SelankNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
Melanotan IINot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
MazdutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
PinealonNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
AHK-CuNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
VK2735Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
ZenagamtideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
PemvidutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial

A blank result means the label or study checked here does not list the reaction. It does not prove the reaction cannot happen, and it does not replace the full prescribing information. A pharmacist or clinician can review the complete label alongside the rest of a person’s medicines.

What people reported to the FDA

The first table summarizes labels and published trials. This table shows reports filed with the FDA after the medicines went on sale. Each percentage is the share of reports for that product that mention this symptom—not the share of patients who experienced it.

Each GLP-1 brand in the FDA snapshot, and what share of its reports names this symptom.
ProductShare of its own reportsAll reports
Ozempicsemaglutidebelow 2.3% of Ozempic reports66,161 reports
Trulicitydulaglutidebelow 2.1% of Trulicity reports88,332 reports
Rybelsussemaglutidebelow 2.1% of Rybelsus reports7,379 reports
Wegovysemaglutidebelow 2.0% of Wegovy reports21,044 reports
Zepboundtirzepatide1.9% of Zepbound reports70,141 reports
Saxendaliraglutidebelow 1.9% of Saxenda reports10,040 reports
Mounjarotirzepatide1.7% of Mounjaro reports93,975 reports
Victozaliraglutidebelow 1.7% of Victoza reports44,086 reports

A row reading “below” is not a zero. The snapshot keeps each product’s 25 most-reported terms, so a term missing from that list was either never reported or reported and ranked 26th. All that can be proved is that it sits under the 25th. Read from FDA on 2026-08-17.

Reports are not rates and a report is not proof the drug did it. How to read this data, and the questions it answers on its own.

3Read deeperWhy it happens, when it appears, and what the page proves

Why the question is nearly always about sulfur

The searches behind this page rarely say burping on its own. They say sulfur burps, or egg burps, and they name a tirzepatide brand while doing it. That is a specific enough complaint that it is worth stating plainly what this site can and cannot do with it.

FDA files these reports under the general MedDRA term for belching. Smell is not recorded, so the data cannot confirm or rule out the sulfur description.

The general belching term appears for the two tirzepatide brands, while the stomach-emptying term appears for semaglutide products. Both findings come from the same FDA reporting system.

Why the label side is empty rather than negative

A blank row means the source we reviewed did not list burping. It does not prove the effect never happens or that no other document mentions it. Trial reports and label summaries do not reproduce every event in full.

This page is the clearest case in the section for why that distinction is kept. If an absence were published as a negative finding, this page would say these compounds do not cause burping — while the other document on the same page shows it among the most-filed complaints about two of them. The absence is about the extract, not about the world.

What this page does and does not establish

This is a page with a real finding and a small one, and the distance between those is where pages on this question usually go wrong.

The claimWhat the evidence shows
Both measured rows are tirzepatide products.Established for those two brands. Zepbound and Mounjaro carry the term among their stored twenty-five; the other six sit below their own ceilings.
Tirzepatide causes more burping than semaglutide.Not established. A share of reports is not a rate, and report volume tracks how long a product has been sold, how it is marketed and what people have been told to expect, as well as biology.
The six dashed rows mean those brands do not cause it.Not established, and the row does not say that. It says the term sits at or below that product’s twenty-fifth most-reported, which is a ceiling, not a zero.
The reports confirm the sulfur description.Not supported either way. FDA records belching under one general term and does not record smell.
No label lists burping.Overstated. None of the extracted label or trial summaries lists it. Check the complete prescribing label for a specific product.

Taking this to a clinician

Belching on its own is a nuisance rather than a warning sign, and nothing on this page suggests otherwise.

ClinicianIt is worth raising when it arrives with severe or persistent abdominal pain, which is how these labels describe the presentation of the serious reactions they do carry. Recognition is the only job of this section. Nothing here is a reason to start, stop or change a treatment, and that decision belongs to the prescribing clinician in every case.

Common questions

Are sulfur burps a listed side effect of Zepbound or Mounjaro?

Not in the tirzepatide side-effect summary used for both brands.

FDA adverse-event data includes the general belching term for both brands but records nothing about smell, so it cannot answer the sulfur part specifically.

Why do the two measured rows matter if the numbers are small?

Because which products carry a term is a separate question from how large the share is, and it is the one this table can answer more confidently.

Both measured rows involve tirzepatide, but report counts cannot prove that the pattern is caused by the drug’s biology.

Is this the same as the gastroparesis question?

It is the same instrument read for a different term, and it comes out the other way round.

The stomach-emptying term appears with semaglutide products, while belching appears with tirzepatide products. Because both come from voluntary FDA reports, neither split proves a property of the molecule.

What would actually answer this?

A trial that recorded belching as an outcome, in a defined population, against a comparison group not taking the compound.

No source cited on this page is that. Until one exists, what this site can offer is the two documents it holds, kept apart, with what each one is stated on it.

Want the full picture for one compound? Open its guide for uses, dosage information, side effects and serious warnings.

Tirzepatide reactions in full, including burping

Information from an approved label behind tirzepatide, apart from burping.

What else semaglutide lists besides burping

Including the semaglutide boxed warning, on the semaglutide page rather than on burping.

Constipation read the same way as burping

8 of 36 pages carry constipation, counted class-wide rather than within burping.

Nausea across every page, as with burping

Which sources name nausea, under what wording and at what frequency, beyond burping.

All source-checked pages, not only those listing burping

From label-backed entries to compounds with no established human dose, including Burping

The burping question, asked about duration

A frequency band counts people rather than days, which is why it cannot answer this, with burping as context

Vial, water and draw for the burping compounds

U-100, U-50 and U-40 barrels each read differently, including burping

Where burping sits among the symptom questions

Every question against every page, in a single table, including Burping

The whole tirzepatide page, not just burping

Tirzepatide has an approved label, separate from burping.

Every symptom in this section is listed on the symptom questions index.

42primary sources, each with the day we read it — open the documents used on this page